Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

The median overall survival with Libtayo (cemiplimab) was 12 months, compared to 8.5 months for the control group, which was treated with chemo selected by investigators. The study enrolled women ...